Solarplast (R) Supplementation Effects Following High-intensity Resistance Exercise

Kent State University

Status: Enrolling

Conditions: Muscle Damage

Treatments: Dietary Supplement: Solarplast (R); Dietary Supplement: Placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT06432868

927

Details and patient eligibility

About

The primary goal of this investigation is to assess whether Solarplast (R) supplementation will improve recovery following heavy resistance exercise in active adults. The primary questions to be addressed are:

Does Solarplast (R) decrease muscle damage and inflammation associated with heavy resistance exercise?

Does Solarplast (R) reduce the decline in performance associate with heavy resistance exercise?

Researchers will compare Solarplast (R) to a placebo (a look-alike substance that contains no active ingredients) to see if Solarplast (R) is effective at improving recovery.

Participants will be asked to:

Take Solarplast (R) or placebo daily for 4 weeks

Visit the laboratory at least once per week to receive their supplement

Report to the lab for 3 consecutive visits following supplementation to complete a heavy resistance training session and follow-up testing.

Enrollment: 46 estimated patients

Sex: All

Ages: 18 to 35 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Recreationally-active (participated in at least 2 weight training workouts per week over the previous year) and participates in at least 3h of total structured exercise/week as determined by the health and activity questionnaire.
• Subject is judged by the Investigator to be healthy and free of any physical limitations (determined by health and activity questionnaire)
• Subject has a body mass index of 18.0-34.9 kg/m2, inclusive
• Subject is willing to maintain habitual diet throughout the study period
• Subject is willing to abstain from dietary supplementation throughout the duration of the study.
• Subject understands the study procedures and signs forms providing informed consent to participate in the study and authorization for release of relevant protected health information to the study Investigators

Exclusion criteria

• Subject is currently or will be enrolled in another clinical trial.
• Subject is a habitual consumer of tea/antioxidants defined as > 8 oz/day of either green or black tea within the 14 days prior to the screening visit.
• Subject has a history or presence of a clinically relevant cardiac, renal, hepatic, endocrine (including diabetes mellitus), pulmonary, biliary, gastrointestinal, pancreatic, or neurologic disorder.
• Subject has a history or presence of cancer in the prior 2 years, except for non-melanoma skin cancer.
• Subject is unable to perform physical exercise (determined by health and activity questionnaire)
• Subject is engaged in an extreme diet including but not limited to, Atkins, South Beach, Intermittent Fasting, etc.
• Subject is allergic to the study product or placebo
• Subject is taking any other nutritional supplement or performance enhancing drug (determined from health and activity questionnaire)
• Subject has any chronic illness that causes continuous medical care
• Taking any type of prescription or over-the-counter medication including but not limited to corticosteroids, non-steroidal anti-inflammatory drugs, and antibiotics within the 14 days prior to the screening visit.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

46 participants in 2 patient groups, including a placebo group

Solarplast (R)

Active Comparator group

Description:

100mg/day of Solarplast (R) supplementation (28 days).

Treatment:

Dietary Supplement: Solarplast (R)

Placebo

Placebo Comparator group

Description:

100mg/day of Placebo (maltodextrin (98.8%) and medium chain triglycerides (1.2%)).

Treatment:

Dietary Supplement: Placebo